Alkermes Completes Enrollment For Registration Study Of VIVITROL(R) In Patients With Opioid Dependence
Alkermes, Inc. (NASDAQ: ALKS) announced that it has completed patient enrollment for the registration study of VIVITROL® (naltrexone for extended-release injectable suspension) for the treatment of opioid dependence, a chronic brain disease. The data from this study will form the basis of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for VIVITROL for this indication. VIVITROL is a once-monthly, intramuscular injection approved in the U.S.
More: continued here
Filed under: Alcohol / Addiction / Illegal Drugs on April 26th, 2009
You must be logged in to post a comment.